Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.BO)
INR 42.72
(0.73%)
INR 42.72
(0.73%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -18.44 Million INR | -471.67% |
| 2022 | 4.96 Million INR | 55.24% |
| 2021 | 3.19 Million INR | 3087.85% |
| 2020 | -107 Thousand INR | -101.14% |
| 2019 | 9.36 Million INR | -37.65% |
| 2018 | 15.01 Million INR | 26.77% |
| 2017 | 11.84 Million INR | 5.87% |
| 2016 | 11.18 Million INR | -5.95% |
| 2015 | 11.89 Million INR | -58.31% |
| 2014 | 28.52 Million INR | 5.99% |
| 2013 | 26.91 Million INR | 1.1% |
| 2012 | 26.61 Million INR | 19.15% |
| 2011 | 22.34 Million INR | 84.95% |
| 2010 | 12.07 Million INR | -58.92% |
| 2009 | 29.4 Million INR | -42.2% |
| 2008 | 50.88 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | 575 Thousand INR | -89.14% |
| 2023 Q2 | 5.29 Million INR | 1304.51% |
| 2023 FY | -18.44 Million INR | -471.67% |
| 2023 Q4 | -18.44 Million INR | -3307.99% |
| 2023 Q1 | 377 Thousand INR | -92.4% |
| 2022 Q3 | 1.61 Million INR | -55.78% |
| 2022 FY | 4.96 Million INR | 55.24% |
| 2022 Q1 | 1.45 Million INR | -54.64% |
| 2022 Q4 | 4.96 Million INR | 208.07% |
| 2022 Q2 | 3.64 Million INR | 151.24% |
| 2021 FY | 3.19 Million INR | 3087.85% |
| 2021 Q4 | 3.19 Million INR | 117.48% |
| 2021 Q2 | 4.25 Million INR | -3.38% |
| 2021 Q3 | 1.47 Million INR | -65.46% |
| 2021 Q1 | 4.4 Million INR | 4216.82% |
| 2020 Q3 | 2.97 Million INR | -46.72% |
| 2020 Q1 | 2.56 Million INR | -72.65% |
| 2020 Q2 | 5.57 Million INR | 117.81% |
| 2020 FY | -107 Thousand INR | -101.14% |
| 2020 Q4 | -107 Thousand INR | -103.6% |
| 2019 Q2 | 13.69 Million INR | 905.73% |
| 2019 FY | 9.36 Million INR | -37.65% |
| 2019 Q4 | 9.36 Million INR | 348.92% |
| 2019 Q1 | 1.36 Million INR | -90.93% |
| 2019 Q3 | 2.08 Million INR | -84.78% |
| 2018 Q4 | 15.01 Million INR | 739.07% |
| 2018 Q3 | 1.78 Million INR | -88.78% |
| 2018 Q2 | 15.95 Million INR | 325.9% |
| 2018 FY | 15.01 Million INR | 26.77% |
| 2018 Q1 | 3.74 Million INR | -68.37% |
| 2017 Q3 | 2.87 Million INR | -76.2% |
| 2017 Q2 | 12.08 Million INR | 290.12% |
| 2017 Q1 | 3.09 Million INR | -72.31% |
| 2017 Q4 | 11.84 Million INR | 311.86% |
| 2017 FY | 11.84 Million INR | 5.87% |
| 2016 Q4 | 11.18 Million INR | 85.77% |
| 2016 Q3 | 6.02 Million INR | -27.94% |
| 2016 Q1 | 1.8 Million INR | -84.8% |
| 2016 FY | 11.18 Million INR | -5.95% |
| 2016 Q2 | 8.35 Million INR | 362.04% |
| 2015 Q1 | 1.27 Million INR | -95.53% |
| 2015 FY | 11.89 Million INR | -58.31% |
| 2015 Q4 | 11.89 Million INR | 286.52% |
| 2015 Q3 | 3.07 Million INR | -88.63% |
| 2015 Q2 | 27.06 Million INR | 2021.05% |
| 2014 Q3 | 1.72 Million INR | -93.19% |
| 2014 Q2 | 25.34 Million INR | -10.5% |
| 2014 FY | 28.52 Million INR | 5.99% |
| 2014 Q4 | 28.52 Million INR | 1551.92% |
| 2014 Q1 | 28.32 Million INR | 5.24% |
| 2013 FY | 26.91 Million INR | 1.1% |
| 2013 Q2 | 27.81 Million INR | 1995.8% |
| 2013 Q1 | 1.32 Million INR | -95.01% |
| 2013 Q3 | 1.67 Million INR | -93.97% |
| 2013 Q4 | 26.91 Million INR | 1504.3% |
| 2012 Q4 | 26.61 Million INR | 24.73% |
| 2012 Q3 | 21.34 Million INR | 0.0% |
| 2012 FY | 26.61 Million INR | 19.15% |
| 2011 Q4 | 22.34 Million INR | 0.0% |
| 2011 FY | 22.34 Million INR | 84.95% |
| 2010 FY | 12.07 Million INR | -58.92% |
| 2009 FY | 29.4 Million INR | -42.2% |
| 2008 FY | 50.88 Million INR | 0.0% |
| 2008 Q4 | 50.88 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 100.477% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 100.499% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 99.351% |
| Granules India Limited | 9.28 Billion INR | 100.199% |
| Indoco Remedies Limited | 6.47 Billion INR | 100.285% |
| Achyut Healthcare Limited | -3.74 Million INR | -392.419% |
| Ajanta Pharma Limited | -954.9 Million INR | 98.068% |
| Alkem Laboratories Limited | -1.6 Billion INR | 98.854% |
| Alpa Laboratories Limited | 35.36 Million INR | 152.162% |
| Brooks Laboratories Limited | 49.48 Million INR | 137.276% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 99.632% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 100.559% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 98.407% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 100.143% |
| Eris Lifesciences Limited | 13.8 Billion INR | 100.134% |
| FDC Limited | -57.75 Million INR | 68.06% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 99.57% |
| Gufic Biosciences Limited | 3.19 Billion INR | 100.577% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 99.556% |
| Ipca Laboratories Limited | 11.41 Billion INR | 100.162% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 98.673% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 100.954% |
| Lasa Supergenerics Limited | 205.79 Million INR | 108.963% |
| Laurus Labs Limited | 24.38 Billion INR | 100.076% |
| Lupin Limited | 17.19 Billion INR | 100.107% |
| Mankind Pharma Limited | -9.9 Billion INR | 99.814% |
| Medicamen Biotech Limited | 160.31 Million INR | 111.506% |
| Medico Remedies Limited | 78.67 Million INR | 123.445% |
| Megasoft Limited | 1.28 Billion INR | 101.435% |
| NATCO Pharma Limited | -5.81 Billion INR | 99.683% |
| Piramal Pharma Limited | 42.27 Billion INR | 100.044% |
| RPG Life Sciences Limited | -364.7 Million INR | 94.942% |
| Sigachi Industries Limited | 859.94 Million INR | 102.145% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 99.975% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 112.723% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 139.917% |
| Unichem Laboratories Limited | 931.91 Million INR | 101.979% |
| Wanbury Limited | 1.1 Billion INR | 101.668% |
| Windlas Biotech Limited | -273.04 Million INR | 93.244% |
| ZIM Laboratories Limited | 983.6 Million INR | 101.875% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 100.472% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 98.041% |
| Divi's Laboratories Limited | -39.77 Billion INR | 99.954% |
| Hester Biosciences Limited | 2.29 Billion INR | 100.805% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 99.214% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 92.586% |
| Bal Pharma Limited | 1.26 Billion INR | 101.46% |
| Strides Pharma Science Limited | 23.25 Billion INR | 100.079% |
| Venus Remedies Limited | -267.7 Million INR | 93.109% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 100.706% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 100.3% |
| Shilpa Medicare Limited | 9.06 Billion INR | 100.203% |
| Aarti Drugs Limited | 5.54 Billion INR | 100.332% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 98.325% |
| Suven Life Sciences Limited | -1.63 Billion INR | 98.87% |
| Ind-Swift Limited | 9.5 Billion INR | 100.194% |
| Valiant Laboratories Limited | -295.03 Million INR | 93.748% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 100.654% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 100.184% |
| Themis Medicare Limited | 764.96 Million INR | 102.411% |
| Hikal Limited | 7.96 Billion INR | 100.232% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 100.058% |
| Sequent Scientific Limited | 4.17 Billion INR | 100.441% |
| Novartis India Limited | -5.89 Billion INR | 99.687% |
| Wockhardt Limited | 18.27 Billion INR | 100.101% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 100.068% |
| Neuland Laboratories Limited | -214.05 Million INR | 91.383% |
| Morepen Laboratories Limited | -231.17 Million INR | 92.021% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 115.367% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 101.89% |